Atai Life Sciences N.V. ATAI · NASDAQ
$7.35 +0.68% (+$0.05)
Summary
33 / 100 · Bulios Score
What speaks for it
- Revenue grew by 160% a year over the last 3 years.
- It holds more cash than debt: $168.8M against $4.29M.
What to watch
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 47% this fiscal year.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 160% a year over the last 3 years. For the next fiscal year analysts expect revenue to fall by 47%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $668.2M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 91.84%
You receive $6.75 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 8
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.